The landscape for Alzheimer’s disease diagnosis has changed significantly over the past decade, but there is still only one conditionally FDA-approved medication. Despite extensive research and many expensive clinical trials, more than 200 investigational programs have failed or been abandoned in the past 10 years alone. New treatments are needed to prevent Alzheimer’s, delay its...
With billions of neurons, the brain is the most complex organ in the body, so it’s not surprising that neuroscience clinical trials—more so than trials in other medical specialties—face major challenges. Despite volume of research and funding, neuroscience clinical trials continue to fail for many reasons. Among them, lack of reliable biomarkers, subjective outcome parameters,...
Meet Our Speakers: Andreas Schreiner, M.D.Senior Vice President, Medical Affairs, Neuroscience and Analgesia Adam SimmonsExecutive Director, Program Strategy, Neuroscience
July 20th, 202311:00 a.m. EDT With billions of neurons, the brain is the most complex organ in the body, so it’s not surprising that neuroscience clinical trials—more so than trials in other medical specialties—face major challenges. Despite volume of research and funding, neuroscience clinical trials continue to fail for many reasons. Among them, lack of...
Leveraging Rare Disease Insights Powered by the CENTOGENE Biodatabank and Centralized Multiomic Laboratories in Clinical Trials MORRISVILLE, N.C., and CAMBRIDGE, Mass., ROSTOCK, Germany, and BERLIN, January 9, 2023 — Premier Research, whose mission is to help the most innovative biotech and medtech companies take their best ideas from concept to commercialization, and Centogene N.V. [Nasdaq:...
Clinical research into neurological diseases is often hindered by a myriad of patient related problems. What can be done to overcome these issues and improve the efficacy of neuroscience trials? In the wake of the pandemic, new opportunities and challenges for neuroscience clinical trials are emerging. After years of slow progress, mental health is now...
The landscape for Alzheimer’s disease diagnosis has changed significantly over the past decade, but there is still only one conditionally FDA-approved medication. Despite extensive research and many expensive clinical trials, more than 200 investigational programs have failed or been abandoned in the past 10 years alone. New treatments are needed to prevent Alzheimer’s, delay its...
September 15th, 202210:00am EDT The landscape for Alzheimer’s disease diagnosis has changed significantly over the past decade, but there is still only one conditionally FDA-approved medication. Despite extensive research and many expensive clinical trials, more than 200 investigational programs have failed or been abandoned in the past 10 years alone. New treatments are needed to...
November 17-20, 2022 Boca Raton, FL Patron Sponsor Attend CNS Summit and gain access to emerging technologies with practical applications, curated networking and idea sharing, and collaborative opportunities to propel the future of drug development. Be sure not to miss Premier Research’s reception on Thursday, November 17, at 8:30p.m.
Background Psychiatric conditions are complex, chronic, often debilitating diseases, and there remains a persistent need for novel medications with proven efficacy and safety. Many of the established antipsychotic agents are highly effective but are associated with significant side effects that may negatively impact adherence and patients’ experiences with treatment. Thus, recent research has focused on...